BarcoPharma and PATHFAST®: Redefining Urgent Diagnostics in Iraq

BarcoPharma is proud to announce its exclusive partnership with PATHFAST®, a next-generation diagnostic platform developed by LSI Medience Corporation – Japan. This strategic collaboration brings cutting-edge point-of-care technology to Iraq, enabling healthcare professionals to deliver rapid, accurate, and laboratory-quality results where and when they are needed most.
PATHFAST® is powered by magnetic particle chemiluminescence technology (MPCL), providing high-sensitivity and specificity in just a few minutes. With its compact design and minimal sample requirements, it integrates seamlessly into emergency departments, intensive care units, and other critical care settings. Its assays are FDA-approved and CE-marked, ensuring global quality standards.
Renowned for its high-sensitivity troponin I testing, PATHFAST® also offers a focused panel of essential biomarkers, including NT-proBNP, D-dimer, hsCRP, CK-MB, myoglobin, and procalcitonin. This allows clinicians to make fast, confident decisions in diagnosing cardiac events, infections, inflammation, and other time-sensitive conditions.
Through this partnership, BarcoPharma reinforces its commitment to advancing diagnostic capabilities across Iraq by introducing trusted global innovations that support better patient outcomes and more efficient clinical workflows
PHC Holdings Corporation